FARS2: An Overview
FARS2 deficiency is an extremely rare inherited genetic disorder that affects the body's ability to produce energy. It primarily affects the nervous system, causing symptoms that can range from severe seizures and developmental disabilities in infancy to progressive difficulties with walking and movement later in childhood.
Although FARS2 deficiency currently has no cure, advances in genetic medicine are opening new possibilities for treatment. Researchers are exploring ways to address the disease's underlying cause, improve cellular function, and help affected individuals maintain mobility and independence.
What Causes FARS2 Deficiency?
FARS2 deficiency is caused by changes, or mutations, in a gene called FARS2. This gene provides instructions for producing an enzyme that plays an essential role in the functioning of mitochondria—the tiny structures inside our cells that generate most of the energy our bodies need.
When the FARS2 enzyme doesn't work properly, mitochondria can struggle to produce energy efficiently. This particularly affects tissues with high energy demands, including the brain, spinal cord, and muscles.
FARS2 deficiency is an autosomal recessive disorder, meaning:
A child typically inherits one altered copy of the FARS2 gene from each parent.
Parents who carry only one altered copy generally have no symptoms.
When both parents are carriers, each pregnancy has a 25% chance of producing a child with FARS2 deficiency.
What Are the Symptoms?
FARS2 deficiency varies considerably in severity. Researchers generally recognize two major forms of the disease, although symptoms can overlap.
1. Early-Onset Epileptic Encephalopathy
This more severe form typically appears during infancy and may involve:
Frequent, difficult-to-control seizures
Significant developmental delays
Weak muscle tone and impaired motor development
Feeding difficulties and poor growth
Elevated lactic acid levels, reflecting problems with energy metabolism
Progressive neurological impairment
Children with this form can experience life-threatening complications.
2. Later-Onset Spastic Paraplegia
This form generally has a less severe course, with symptoms primarily affecting movement and mobility. These can include:
Increasing muscle stiffness, particularly in the legs
Difficulty walking, including toe walking or an unusual gait
Muscle weakness and impaired coordination
Problems with balance and frequent falls
Progressive loss of mobility in some individuals
Other neurological complications in certain cases
Some affected individuals remain ambulatory for many years, while others eventually require mobility aids or wheelchairs.
The progression of FARS2 deficiency is highly variable. Even individuals with similar genetic mutations can experience different symptoms and rates of progression.
How Rare Is FARS2 Deficiency?
FARS2 deficiency is considered an ultra-rare disease. Only a small number of affected individuals have been described in published medical literature, and its true worldwide prevalence remains unknown.
The condition was first identified in the medical literature in 2012. Since then, advances in genetic sequencing have made it easier to diagnose, although some affected individuals may remain unidentified.
Because the disease is so rare, families often face significant obstacles:
Limited information about long-term prognosis
Few physicians with direct experience treating FARS2 deficiency
No established disease-modifying treatment
Limited research funding and clinical trial opportunities
Difficulty connecting with other affected families
These challenges make international collaboration among families, scientists, and medical institutions especially important.
How Is FARS2 Deficiency Diagnosed?
Diagnosis generally involves genetic testing, often through whole-exome or whole-genome sequencing, to identify disease-causing variants in both copies of the FARS2 gene.
Physicians may also use neurological examinations, brain imaging, metabolic testing, and assessments of muscle function to better understand the disease's effects.
Early and accurate diagnosis can help families obtain appropriate medical care and participate in emerging research.
What Treatments Are Available?
There is currently no approved treatment that corrects the underlying genetic defect in FARS2 deficiency. Medical care focuses on managing symptoms and preserving function.
Depending on an individual's needs, treatment may include:
Physical and occupational therapy to maintain strength, flexibility, and mobility
Medications to manage seizures, muscle stiffness, and other symptoms
Mobility supports, including braces, walkers, and assistive technologies
Nutritional and supportive care to address feeding and metabolic complications
Why Is There Hope for New Treatments?
Rapid advances in genetic medicine are creating opportunities that were unimaginable when FARS2 deficiency was first identified.
Three approaches are especially promising:
Gene therapy: Developing methods to deliver a functioning copy of the FARS2 gene to affected cells.
Drug repurposing: Investigating existing medications and other compounds that might improve mitochondrial function or reduce symptoms.
Assisted movement: Using rehabilitation strategies and emerging technologies to preserve mobility and independence.
These approaches remain investigational or supportive; none has yet been proven to cure FARS2 deficiency.
Why FARS2 Research Matters Beyond This Disease
Thousands of rare genetic disorders affect small numbers of patients, making conventional drug development difficult and expensive.
FARS2 research offers an opportunity to demonstrate how families, scientists, and research institutions can work together to accelerate treatment development for even the rarest conditions.
Progress in developing gene therapies, identifying promising drugs, and building efficient research models could help establish approaches that other rare disease communities can adapt.
Our goal is not simply to advance treatments for FARS2 deficiency. It's to help demonstrate that even the rarest diseases can be tackled—and that breakthroughs for a few patients can help open the door to treatments for many more.